Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). - Wikidata - awgldk - TriplyDB

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

http://www.wikidata.org/entity/Q45180301

about

Antiviral action of the tumor suppressor ARF Oncolytic Replication of E1b-Deleted Adenoviruses Ral GTPase down-regulation stabilizes and reactivates p53 to inhibit malignant transformation A dynamical systems model for combinatorial cancer therapy enhances oncolytic adenovirus efficacy by MEK-inhibition Replicating adenoviruses that target tumors with constitutive activation of the wnt signaling pathway Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses Heterochromatin silencing of p53 target genes by a small viral protein.ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway?Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer.Replication-selective virotherapy for cancer: Biological principles, risk management and future directions.Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.Comparative effect of oncolytic adenoviruses with E1A-55 kDa or E1B-55 kDa deletions in malignant gliomas 2-aminopurine enhances the oncolytic activity of an E1b-deleted adenovirus in hepatocellular carcinoma cells.Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA.Oncolytic adenoviruses for treatment of brain tumours.Intravascular adenoviral agents in cancer patients: lessons from clinical trials.MDM2 promotes ubiquitination and degradation of MDMX pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes.Tissue-specific promoters for cancer gene therapy.A comprehensive analysis of radiosensitization targets; functional inhibition of DNA methyltransferase 3B radiosensitizes by disrupting DNA damage regulation.The use of gene therapy in cancer research and treatment.An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.Replication-selective oncolytic viruses in the treatment of cancer.Conditionally replicating adenoviruses for cancer treatment.The tumor suppressor gene TP53: implications for cancer management and therapy.Gene- and immunotherapy for hepatocellular carcinoma.The feasibility of gene therapy in the treatment of head and neck cancer Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein Gene therapy for bladder cancer using E1B-55 kD-deleted adenovirus in combination with adenoviral vector encoding plasminogen kringles 1-5.Armed replicating adenoviruses for cancer virotherapy.Adenoviral vector-based strategies for cancer therapy.Emerging roles of p53 and other tumour-suppressor genes in immune regulation Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.Oncolytic viruses in the treatment of cancer: a review of current strategies.Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B-55K protein Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes.

P2860

Q24301787-ADD052E5-3547-45BF-98F6-9F4DF578FBF4 Q26777406-782A3F13-6886-4067-AEC6-74C38D2A7BAC Q28247699-985D7D8E-EBC0-4FD4-A396-BC339E14F37D Q28477181-CD53DF55-5A7F-4A45-82FA-D35C300FAB4C Q33865835-5D0AE498-5FF5-42F0-8BF5-3C651F9D19E7 Q33924550-B6251A27-88BD-4450-9C42-B9487BE0F630 Q34091002-6F41E8AF-7075-42C7-A018-9A8531D068CA Q34115253-08941CD7-B292-42A1-9531-EF62CF73175E Q34225918-10D5BDCB-2311-4D77-AF24-9CA35B22A9FC Q34253427-D2D40379-6B91-42F7-BB8C-93B4EFB6A3E2 Q34293607-7A695167-F0C1-4079-BA2A-BEB53DDFEDBB Q34297058-B6C65CC7-39E9-4D75-BECA-3B605A8E2C02 Q34393001-E4ABDE79-0DCD-4984-8351-C1327E57803B Q34452020-7A798038-F3FC-420E-A4C5-CE52508253DD Q34725017-F0DCE10C-734F-4A9B-8163-CA52921E314C Q34764233-71662EFA-42E2-474A-AB9F-8B68C1E5C872 Q35000513-D3C362D2-8616-46BC-A796-1E5091DBAE1E Q35040863-3C9542C8-A77C-48A2-A656-1FDE0AA61ED0 Q35043094-E98275AA-070F-496E-937C-BDEF1EAB7AB0 Q35161842-C4C491CA-D3F0-4EFA-A6B6-37D20183CDE1 Q35569909-23FC78D1-9767-4AA5-A1C2-27258DABD96F Q35648549-1C6DF5E9-935C-43CA-92B9-60BCF920BE38 Q35779378-96EA0EF1-1A29-4A3B-B264-C0000E2202E7 Q35868661-5522E76B-A676-4A4E-90A0-BC2799D1EC83 Q35904008-10D20E88-CBD5-4B2A-8E09-605FA07B4017 Q35911903-C6915E14-C8E6-4237-9FAC-EE95BD288FAB Q35912403-5F893363-2773-4AFB-832E-1CE84133CB04 Q35967313-FA48B7CD-95A4-4840-A80A-BB9A2B60F08C Q35986418-036A0676-7954-451B-B36C-32BEF97BE7D9 Q36150432-4053237A-C4A6-4482-A65D-90DCADD91E6E Q37093159-14BDD9A8-D846-4DD2-8F75-203A553B22E3 Q37290808-CE9C98A7-6A7C-4818-993C-77E77142C76D Q37340383-967D3B21-56F2-4CA1-B195-8CE847762529 Q37386616-158FB174-129E-4F6E-9F9C-1804BED52484 Q37409025-8FF29B90-2395-4973-B208-322764D14F2A Q37666015-CE1F8A27-9AD2-428A-AABE-191F7E409083 Q37733550-78EAEA27-0F00-46BC-B138-77E3A97ECB4A Q38020107-5390786B-BD7A-47DD-9A2C-63CE2804B06E Q39602482-F11C3FF8-5178-41D5-A202-3999E45BCBB5 Q39685569-220718DB-7E79-40C0-A9B6-4E9D0CD46A1D

P2860

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

http://www.wikidata.org/entity/Q45180301

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh-hant

name

Loss of p14ARF in tumor cells ...... irus mutant dl1520 (ONYX-015).

@en

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520

@nl

type

label

Loss of p14ARF in tumor cells ...... irus mutant dl1520 (ONYX-015).

@en

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520

@nl

prefLabel

Loss of p14ARF in tumor cells ...... irus mutant dl1520 (ONYX-015).

@en

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520

@nl

P1433

Q45180301-E56F127A-4BA4-42C2-ADE1-4E26FE4BE3F2

P1476

Q45180301-F3D518C7-1C9C-4A4C-BE95-6632B177819B

P2093

Q45180301-0E8D1380-BA7D-47DC-B594-15D088186259

Q45180301-19DEFB0F-0BB3-4899-9296-E7F661D6F82C

Q45180301-55DF2A83-DBA3-4E68-A4EB-C993F4239562

Q45180301-64C51E2E-43A9-4B57-9191-55748947EB45

Q45180301-72D3F411-B1E8-4E57-9062-DACE98D83603

Q45180301-BB6F0B9F-6847-4300-B2D6-7A8DD880D813

Q45180301-C1DD07B7-6445-48C6-A0E7-2446280A1A14

P2860

Q45180301-02AD57E6-A4B8-42FE-9F39-9B61B8539A19

Q45180301-0B9296C2-A2B8-4175-B396-9F3CE864D1F9

Q45180301-225C4F14-CB5C-43CE-AC55-C32F41743C76

Q45180301-2A3731DC-6E97-4781-A5E6-12173D271D9C

Q45180301-3933C3A7-4DD9-4EAA-A94E-22C95703F85E

Q45180301-44898565-F1D7-4FDD-A9A6-57095A017225

Q45180301-4E49384F-6E65-4D3C-A0D7-5BB7BDBDEB33

Q45180301-6729D8B8-F773-42FB-B9B5-F69560E44617

Q45180301-7123CAD5-5779-4439-A3ED-F2461A5042EA

Q45180301-7B1F69B3-F70D-4BB3-AAF9-3818157983EF

P2888

Q45180301-272AA227-56E1-42CF-8BF5-AEAA0CCA38E5

P304

Q45180301-7B3F5B55-4E4C-4130-940A-981B8B22FE36

P31

Q45180301-A2795B3A-F0C5-47D1-AF6E-86AC4434FC9A

P356

Q45180301-BF820FFC-ED9D-434C-B20A-A43C8528E072

P407

Q45180301-FC903932-04A8-4F17-ACF4-769413110275

P433

Q45180301-0A400761-DB41-48A8-AE94-9D7D452CD9D5

P478

Q45180301-3446FFBA-ADFD-41B7-86D2-A92999FB1CB1

P50

Q45180301-5F5DF3B2-8709-45BD-BDF8-ED4E8EBEF937

P577

Q45180301-99E9444F-1A23-449A-813A-8883523D4C44

P5875

Q45180301-1BBE4472-E1C2-4C28-8F53-79A71070C6D3

P6179

Q45180301-DDA0A615-4008-4C7E-88CA-8C63E5C24CC3

P698

Q45180301-A516B92B-96B1-4F1D-9B9B-9B0DE0E5CF09

P921

Q45180301-CEF992C9-43CF-4494-86E8-99A1C01F8A08

P356

P1433

Nature Medicine

P1476

Loss of p14ARF in tumor cells ...... virus mutant dl1520 (ONYX-015)

@en

P2093

A S Chung

http://www.w3.org/2001/XMLSchema#string

B C Hann

http://www.w3.org/2001/XMLSchema#string

C H Biederer

http://www.w3.org/2001/XMLSchema#string

E M Lipner

http://www.w3.org/2001/XMLSchema#string

F McCormick

http://www.w3.org/2001/XMLSchema#string

S J Ries

http://www.w3.org/2001/XMLSchema#string

W M Korn

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in human ARF exon 2 disrupt its nucleolar localization and impair its ability to block nuclear export of MDM2 and p53

DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts

P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

Clonal analysis of human colorectal tumors

Requirement for p53 and p21 to sustain G2 arrest after DNA damage

Nucleolar Arf sequesters Mdm2 and activates p53

Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.

P2888

P304

1128-1133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/80466

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Christian H Brandts

P577

2000-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12306887

http://www.w3.org/2001/XMLSchema#string

P6179

1046045283

http://www.w3.org/2001/XMLSchema#string

P698

11017144

http://www.w3.org/2001/XMLSchema#string

P921